Interval Partners LP Takes Position in Enfusion, Inc. (NYSE:ENFN)

Interval Partners LP purchased a new stake in Enfusion, Inc. (NYSE:ENFN) in the 4th quarter, Holdings Channel.com reports. The firm purchased 288,379 shares of the company’s stock, valued at approximately $2,970,000.

Several other hedge funds and other institutional investors have also modified their holdings of ENFN. Rhumbline Advisers lifted its position in Enfusion by 3.0% in the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after purchasing an additional 1,796 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Enfusion by 19.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,746 shares of the company’s stock valued at $204,000 after purchasing an additional 3,238 shares during the last quarter. Legal & General Group Plc lifted its position in Enfusion by 9.5% in the 4th quarter. Legal & General Group Plc now owns 45,289 shares of the company’s stock valued at $466,000 after purchasing an additional 3,938 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Enfusion by 3.3% in the 4th quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock valued at $1,303,000 after purchasing an additional 4,032 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Enfusion by 58.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock valued at $136,000 after purchasing an additional 4,889 shares during the last quarter. 81.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th.

Insider Transactions at Enfusion

In related news, CEO Oleg Movchan sold 2,790 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $32,029.20. Following the completion of the sale, the chief executive officer now directly owns 643,299 shares of the company’s stock, valued at approximately $7,385,072.52. This represents a 0.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Neal Pawar sold 2,769 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the sale, the chief operating officer now directly owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. This represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,223 shares of company stock worth $754,778 in the last 90 days. 36.44% of the stock is owned by insiders.

Enfusion Price Performance

Enfusion stock opened at $10.85 on Monday. The firm’s 50 day simple moving average is $10.95 and its 200-day simple moving average is $10.63. The company has a market cap of $1.40 billion, a P/E ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million for the quarter, compared to analysts’ expectations of $53.98 million. On average, analysts expect that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.